Streetbeat News

CGON

Cg Oncology Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

33.05

Mkt cap

2.3B

Volume

67K

High

34.10

P/E Ratio

-2.12

52-wk high

50.23

Low

32.55

Div yield

N/A

52-wk low

25.77

Top Wall Street analysts initiated coverage on several companies with bullish ratings. Notable initiations include WidePoint Corporation, Syndax Pharmaceuticals, Sempra, Tenax Therapeutics, and CG Oncology, all receiving Buy or Outperform ratings with significant price targets.

Portfolio Pulse from Avi Kapoor

October 24, 2024 | 11:40 am

UBS analyst David Dai has initiated coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:26 am

B of A Securities analyst Charlie Yang has reiterated a Buy rating for CG Oncology (NASDAQ:CGON) with a maintained price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:41 pm

RBC Capital has initiated coverage on CG Oncology with an Outperform rating and set a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:08 am

HC Wainwright & Co. has reiterated its Buy rating for CG Oncology (NASDAQ:CGON) and maintained a price target of $75, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:44 am

Roth MKM has initiated coverage on CG Oncology with a Buy rating and set a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:24 pm

CG Oncology shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 5:01 pm

CG Oncology (NASDAQ:CGON) reported a Q2 2024 adjusted EPS of $(0.28), beating the analyst consensus estimate of $(0.41) by 31.71%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:34 pm

Nine analysts have provided varied opinions on CG Oncology (NASDAQ:CGON) over the past quarter, with the majority being bullish. The average 12-month price target is $68.33, slightly down from the previous $69.67. Key analysts from firms like B of A Securities, HC Wainwright & Co., and Goldman Sachs have maintained or raised their ratings, with price targets ranging from $50.00 to $75.00. CG Oncology is a late-stage clinical biopharmaceutical company focused on bladder cancer treatments, showing strong revenue growth but facing profitability challenges.

Portfolio Pulse from Benzinga Insights

June 28, 2024 | 3:01 pm

B of A Securities has initiated coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and a price target of $65, as announced by analyst Charlie Yang.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 10:31 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.